The global interventional cardiology devices market size is expected to reach USD 22.35 billion by 2030, according to a new report by Grand View Research Inc. The market is expected to expand at a CAGR of 7.2% from 2023 to 2030 Demand for interventional cardiology devices is on the rise owing to favorable reimbursement policies for coronary intervention procedures, rising prevalence of cardiovascular diseases (CVDs) and diabetes across the globe, and the launch of new product lines in the market. Cardiovascular diseases have become one of the major causes of mortality and morbidity in the world. Coronary artery disease and congenital heart defects are the major cardiovascular diseases that are prevalent across the globe.
Furthermore, the adoption of unhealthy lifestyles, such as smoking, a sedentary lifestyle, and improper diet, is responsible for diabetes. Cardiac catheterization, angioplasty, and Percutaneous Coronary Intervention (PCI) are some of the major procedures used for the treatment of cardiovascular diseases. Since diabetes is one of the major reasons behind triggering cardiovascular diseases, increasing diabetes cases are expected to surge the demand for interventional cardiology devices over the forecast period. Although the market is anticipated to expand over the coming years, it might witness slower growth possibly brought on by the high price of medical devices, especially in developing economies with insufficient insurance coverage.
Request a free sample copy or view report summary: Interventional Cardiology Devices Market Report
The coronary stents segment dominated the market with the largest revenue share of 64.6% in 2022. DES makes up the majority of sales in the coronary stent category.
Technological advancements in coronary stents, such as the development of bifurcated stents and the use of biodegradable materials, have led to efficient and improved outcomes of CVD treatment. Companies are proactively involved in product developments and partnerships and strategic collaborations. The aforementioned factors are expected to propel industry growth over the forecast period
Asia Pacific region is expected to advance at the fastest CAGR of 7.9% over the forecast period. This growth can be attributed to several factors, including the increasing incidence of coronary artery disease (CAD) and improved screening measures for this disorder.
The market is fragmented due to the presence of several players. This is expected to intensify the competition in the coming years. Market players are adopting various strategic initiatives such as partnerships, sales & marketing activities, mergers & acquisitions, service expansion, integrated offerings, and product launches to increase their market presence
Grand View Research has segmented the global interventional cardiology devices market report based on product and region:
Interventional Cardiology Devices Product Outlook (Revenue, USD Million, 2018 - 2030)
Coronary Stents
DES
BMS
BRS
PTCA Balloon Catheters
Normal
Specialty (Includes cutting, scoring, and lithotripsy balloons)
DCB
Accessory Devices
PTCA Guidewires (Workhorse, Specialty)
Diagnostic Catheters
PTCA Guiding Catheters
Introducer Sheaths
Intravascular Imaging Catheters and Pressure Guidewires (IVUS Catheters, OCT Catheters, FFR Guidewires)
Interventional Cardiology Devices Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
Thailand
South Korea
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
Middle East & Africa
List of Key Players of Interventional Cardiology Devices Market
Abbott Laboratories
Medtronic
Boston Scientific
Spectranetics
Cardinal Health
Philips Healthcare
Terumo
Alvimedica
Teleflex Medical
B. Braun
Biosensors International
Meril Life Sciences
BIOTRONIK
ACIST Medical Systems
ASAHI INTECC
CID Vascular
Cook Medical
Medinol
Merit Medical Systems
NuMED
OpSens
Vascular Solutions
Zeon Medical
"The quality of research they have done for us has been excellent..."